RxDoctor Payments Data

Lauren Pearson, PA

Physician Assistant · Norfolk, VANPI 1366062531

Payments from drug & device makers

$1,027in general payments, 2019–2025

Across 14 payments — averaging $73.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$243
  • AstraZeneca$230
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$116
  • Welch Allyn$104
  • Scpharmaceuticals Inc.$102
  • Sanofi-aventis U.S. LLC$99
  • plus $134 from 2 others

What the payments were for

  • Food & beverage$92490%
  • Other$10410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,027 in reported general payments places this provider in the 70th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$15,969
Medicare patients
162
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$79,993
XareltoRivaroxaban22$33,511
EntrestoSacubitril/Valsartan20$31,052
Repatha SureclickEvolocumab11$6,176
BrilintaTicagrelor12$3,314
Atorvastatin Calcium185$2,328
Metoprolol Succinate97$1,457
Amlodipine Besylate120$1,111
Losartan Potassium85$1,056
Rosuvastatin Calcium62$1,043
ClopidogrelClopidogrel Bisulfate71$1,035
Bumetanide21$884
Carvedilol75$853
Ezetimibe27$777
Isosorbide Mononitrate ErIsosorbide Mononitrate63$762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$230$3,31412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →